INCY Incyte Corp: Earnings per share for the last 12 months

Incyte Corp. (INCY) - corporate logo

Incyte Corporation (INCY) is mitigating risks by expanding its portfolio of medications to combat autoimmune and oncological pathologies. Business growth is driven by the success of Jakafi and the approval of Opzelura. Breakthrough developments in JAK inhibitors are stimulating pipeline growth. The 12-month annual EPS growth trend captures these dynamics, where the value -65.90 describes the company's current yield level.

Incyte Corp. (INCY) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/17/2026
Flagship merchandise of Incyte

This indicator is calculated as the percentage change in the rolling annual net income per share, reflecting the dynamics of capital efficiency. This metric allows an investor to assess the growth rate of business profitability relative to industry averages. For Incyte Corporation (INCY), such dynamics depend directly on the success of costly developments in immuno-oncology and targeted therapy. By analyzing the annual percentage growth of EPS TTM, one can determine how effectively the company's scientific potential is converted into actual profit.

Direct competitors

HCM (HUTCHMED) - Earnings per share for the last 12 months|Nuvation Bio Inc. (NUVB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DAWN|MNPR (monopartx.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months inhibrx.com (INBX)|Earnings per share for the last twelve months I-Mab (IMAB)|FENC - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Heron Therapeutics Inc HRTX|Nuvectis Pharma, Inc - Earnings per share for the last twelve months|CHRS - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Corbus Pharmaceuticals|CRDF: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BeyondSpring Pharma BYSI|Net earnings per share for the last 12 months BCAB|Net earnings per one share for the last twelve months Lixte Biotechnology LIXT|Net earnings per share for the last 12 months CTXR (Citius Pharmaceuticals Inc.)|CLRB (Cellectar Biosciences, Inc.) - Earnings per share for the trailing year|BioLineRx Ltd. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters CANF (Can-Fite BioPharma Ltd.)|Aprea Therapeutics, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KZIA (kaziatherapeutics.com)|SLXN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NuCana Corp (NCNA)|Earnings per share for the last twelve months Chimerix|CYCC: Earnings per share for the trailing year|Net earnings per share (EPS TTM) GTHX|Net earnings per share (EPS TTM) Kronos Bio Corporation (KRON)|Earnings per share for the last twelve months Kintara KTRA|ONCT (Oncternal Therapeutics, Inc.) - Earnings per one share for the last 12 months|PRTG: Net earnings per share for the last 12 months